So the chemically castrated patient, meaning they have no testosterone so if you treat a patient who has no testosterone and you take them from zero testosterone to normal testosterone, so to take them from, let's say, zero to 350, um, during that climb from zero to 350, you can increase theoretically, the risk of exasperating a prostate cancer that's pre pre-existing was the fear
Understanding BPC-157 Body Protection Compound 157, or BPC-157, is a synthetic substance
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
This dual-mechanism approach shows promise for patients with treatment-resistant diabetes and obesity but requires careful medical supervision during dose escalation
An exploratory analysis from the GLORY-1 trial found something particularly noteworthy
